{"id":"bb172b087920","type":"article","url":"https://hartvaat.nl/2026/12/01/biologische-leeftijdversnelling-correleert-met-progressie-van-cardiovasculair-ni/","title":"Biologische leeftijdversnelling correleert met progressie van cardiovasculair-nier-metabool syndroom","title_en":"Biological age acceleration and cardiovascular-kidney-metabolic syndrome progression: evidence from UK Biobank and NHANES.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2026.2738248","source_url":"https://doi.org/10.1080/0886022X.2026.2738248","authors":["Yukai Zhang","Chenwei Zhang","Xin Wang","Yun Zhou"],"significance":5,"published":"2026-10-20","source_date":"2026-12-01","image":"","kennis":[],"congress":"","summary_en":"In a large UK Biobank cohort and NHANES cross-sectional analysis, accelerated biological age was significantly associated with progression to higher cardiovascular-kidney-metabolic (CKM) syndrome stages and greater baseline disease burden. Each 1-SD increase in biological age acceleration yielded hazard ratios of approximately 1.20–1.23 for CKM progression. While the associations are robust across populations, the incremental clinical utility for risk stratification or guiding interventions remains untested.","created":"2026-10-14T00:50:24Z","updated":"2026-10-14T00:50:24Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een grote cohortstudie (UK Biobank) en cross-sectionele analyse (NHANES) bleek versnelling van de biologische leeftijd significant geassocieerd met progressie van het cardiovasculair-nier-metabool (CKM) syndroom en een hogere basaal stadiumbelasting. Per standaarddeviatie toename in biologische leeftijdversnelling was de hazard ratio voor progressie naar een hoger CKM-stadium ongeveer 1,20–1,23. Hoewel de associaties robuust zijn, blijft de toegevoegde klinische waarde voor risicoschatting of interventiesturing ononderzocht.","abstract_original":"OBJECTIVE: We examined associations of biological age acceleration with cardiovascular-kidney-metabolic (CKM) syndrome progression and baseline stage burden. METHODS: Longitudinal analyses included 326,218 UK Biobank participants, and cross-sectional analyses included 5,228 NHANES adults. PhenoAge and KDMAge acceleration were residuals from regressing each biological age measure on chronological age. We modeled two UK Biobank transitions using cause-specific Cox and competing-risk models and compared NHANES stages using survey-weighted logistic regression. RESULTS: Over a median 13.48 years, 2,567 participants progressed from stage 0/1 to stage 2/3 and 42,835 from stage 1 or 2/3 to stage 4. Per 1-SD increment, PhenoAge acceleration was associated with both transitions [hazard ratios (HRs) 1.234, 95% confidence interval (CI) 1.189-1.281; HR 1.208, 95% CI 1.197-1.218]. KDMAge acceleration showed corresponding HRs of 1.229 (95% CI 1.180-1.280) and 1.220 (95% CI 1.207-1.232), all P < 0.001. Results remained directionally consistent after accounting for competing mortality. Associations for dichotomized accelerated aging remained significant after false discovery rate correction, and UK Biobank splines suggested possible non-linearity. In NHANES, PhenoAge acceleration was associated with stages 1, 2/3, and 4 versus stage 0. Corresponding odds ratios (ORs) were 1.154 (95% CI 1.107-1.202), 1.221 (95% CI 1.176-1.268) and 1.333 (95% CI 1.249-1.423), all P < 0.001. KDMAge acceleration ORs were 1.025 (95% CI 1.006-1.044; P = 0.012), 1.038 (95% CI 1.019-1.057; P < 0.001), and 1.041 (95% CI 1.011-1.073; P = 0.010). CONCLUSIONS: Biological age acceleration was associated with CKM progression and baseline burden. KDMAge comparability remains uncertain. Incremental predictive and clinical utility remained untested."}